ライフサイエンスコーパス: immunisation

1 or gaps in optimum diagnosis, treatment, and immunisation.

2 children are unlikely to benefit from active immunisation.

3 achieving full protection with a single dose immunisation.

4 to each of the four vaccine components after immunisation.

5 ssment criteria for adverse events following immunisation.

6 nal correlates of attachment patterns during immunisation.

7 te molecular mechanisms deemed necessary for immunisation.

8 individuals, and the group-level benefits of immunisation.

9 eous cancers, and for intracutaneous genetic immunisation.

10 boosted in vaccinees that received a second immunisation.

11 Opa were specific to the Opa variant used in immunisation.

12 r before to bring about these innovations in immunisation.

13 infant response to BCG, tetanus, or measles immunisation.

14 verse events were associated with receipt of immunisation.

15 lenge was given to all monkeys 28 days after immunisation.

16 stemic immune response resulted from mucosal immunisation.

17 out 14 million individuals, were offered MCC immunisation.

18 continue to have an important role in global immunisation.

19 for human antigens have been obtained after immunisation.

20 gestational age infants was not modified by immunisation.

21 equiring hospitalisation were reported after immunisation.

22 cine-NP and IAV groups following the booster immunisation.

23 o prioritise research directions in maternal immunisation.

24 blingually delivered antigen than intranasal immunisation.

25 ered by intramuscular injection or Nanopatch immunisation.

26 t affect the uptake of recommended childhood immunisations.

27 ds of mortality (2.02 [1.23-3.32]) and lower immunisation (0.34 [0.24-0.47]) than did Han children.

28 After immunisation, 11 (92%) of 12 vaccine-treated participant

29 We studied 14 outcomes-children's immunisations, accidents, language development, positive

30 countries had completed measles supplemental immunisation activities (SIA) in children aged 9 months

31 pants were excluded from local supplementary immunisation activities during the study period.

32 the efficacy of mOPV1 used in supplementary immunisation activities from 2076 matched case-control p

33 V shows a potential role for this vaccine in immunisation activities to accelerate eradication and pr

34 Coverage estimates for immunisation activities were also obtained, allowing for

35 d through polio surveillance, information on immunisation activities with different oral poliovirus v

36 Supplementary immunisation activities with oral poliovirus vaccines (O

37 munity, based on these estimates and planned immunisation activities, were produced through to April

38 3 years after a measles supplemental immunisation activity (SIA), we undertook a cross-sectio

39 dline, and after each round of supplementary immunisation activity for acceptability and effect.

40 uch as WHO but also a well informed national immunisation advisory committee with access to appropria

41 Maternal immunisation against GBS during pregnancy might protect

42 ough scientific evidence to support maternal immunisation against pertussis and influenza is rapidly

43 a number of applications, including passive immunisation against plant pathogens.

44 2007 to form the Journalists Initiatives on Immunisation Against Polio (JAP), to develop communicati

45 ring pregnancy and targeting of children for immunisation against sexually transmitted diseases.

46 e promising for the development of an active immunisation against tumours.

47 s of life, optimum prenatal care, and timely immunisations against the common childhood diseases.

48 ary opportunities to expand the portfolio of immunisations against viral and bacterial diseases and t

49 ecuited infants due to receive their primary immunisations aged up to 13 weeks on first vaccinations

50 ons that can be routinely scheduled, such as immunisation and antenatal care, had much higher coverag

51 tcome) and coverage of interventions such as immunisation and growth monitoring (secondary outcome).

52 require improvements to presently inadequate immunisation and health-service infrastructures, and uni

53 , those examined in our study indicated that immunisation and immunotherapy with DFTD cells expressin

54 in coverage of interventions, especially of immunisation and insecticide-treated bednets.

55 8.5%) and has achieved universal coverage of immunisation and skilled birth attendance, with low ineq

56 iments that are done at long intervals after immunisation and that identify protection as the absence

57 PTH were produced within 4 weeks of initial immunisation and titres increased with repeated doses of

58 that are capable of differentiating between immunisation and true HIV-1 infection.

59 The public needs to regain confidence in immunisation and trust the organisations responsible for

60 he remaining eight participants who received immunisation and who were examined neuropathologically,

61 ld survival through programmes for childhood immunisations and diarrhoeal disease control.

62 evelopment of an infant's immune response to immunisations and unrelated infections.

63 We collected serum samples before and after immunisation, and cord blood from a subset of women and

64 21-51% in 2012 for routine and supplementary immunisation, and most caregivers cited ignorance of eit

65 ternative to conventional needle-and-syringe immunisation, and potentially offer improved immunogenic

66 vement toward co-administration of IPTi with immunisation, and the increase in travellers to malariou

67 f oral polio vaccine (OPV) and other routine immunisations, and to enhance immunity through the intro

68 m selected populations by means of universal immunisation as soon as suitable vaccines become license

69 roviding more immediate protection than does immunisation as well as providing additional protection

70 re significantly more likely to achieve full immunisation at 12 months of age (relative risk 1.09, 95

71 itamin A capsule receipt, complete childhood immunisations, better sanitation, and use of iodised sal

72 s is almost completely preventable by active immunisation, but very rarely unexpected cases can occur

73 llowed up achieved the primary outcome, full immunisation by 12 months of age (296 [82%] of 360 contr

74 ity engagement and maternal and child health immunisation campaigns in insecure and conflict-affected

75 d health and immunisation camps during polio immunisation campaigns was successful in increasing vacc

76 tion and targeted community-based health and immunisation camps during polio immunisation campaigns w

77 realisation of the public health gains that immunisation can achieve in the next decade and beyond--

78 Nevertheless, although compulsory immunisation can be very effective, it might not be acce

79 tion according to either caregiver report or immunisation card.

80 .1%, 95% CI 3.4-22.7), expanded programme on immunisation centres (3.3%, 95% CI 0-6.9), and paediatri

81 nutrition centres, and expanded programme on immunisation centres) in paediatric populations in low-i

82 recruited healthy infants aged 6 weeks at 42 immunisation clinics and randomly assigned them (with bl

83 improved routine or supplementary (campaign) immunisation coverage (multivariable odds ratio [OR] = 0

84 d health staff correlated significantly with immunisation coverage across many world regions.

85 upled with incentives significantly improved immunisation coverage and timeliness.

86 Incomplete immunisation coverage causes preventable illness and dea

87 Survey-based DTP3 immunisation coverage has improved more gradually and no

88 index: a summary measure of the strength of immunisation coverage in a country.

89 pending (0.66, p<0.0001) were informative of immunisation coverage in the Eastern Mediterranean betwe

90 Given that global immunisation coverage levels have stagnated around 85%,

91 ERPRETATION: In a setting with high baseline immunisation coverage levels, SMS reminders coupled with

92 to evaluate the acceptability and effect on immunisation coverage of an integrated strategy for comm

93 ll parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus tox

94 ease outbreaks, reaching and sustaining high immunisation coverage rates, and expediting the introduc

95 s have been invested in increasing childhood immunisation coverage through global initiatives such as

96 Factors associated with DTP3 immunisation coverage varied by world region: personal i

97 el of income does not contribute to improved immunisation coverage.

98 hen monitoring and rewarding improvements in immunisation coverage.

99 dered a key solution to improving the global immunisation coverage.

100 ormation from clinical records was linked to immunisation data held on the child health computing sys

101 us looking into future possibilities such as immunisation during pregnancy and targeting of children

102 success of tetanus, influenza, and pertussis immunisation during pregnancy has led to consideration o

103 Immunisation during pregnancy is a relatively new strate

104 Influenza immunisation during pregnancy is recommended but not wid

105 imilarly, many countries recommend influenza immunisation during pregnancy to reduce the risk of dise

106 tetanus, diphtheria, and acellular pertussis immunisation during pregnancy.

107 asic vaccines from the Expanded Programme of Immunisation (eg, BCG, measles, diphtheria-tetanus-pertu

108 tio) to receive PCV10 in addition to routine immunisations either as a two-dose prime and boost (2+1)

109 ss of the recommended Expanded Programme for Immunisation (EPI) vaccines, this paper identifies predi

110 interactions with the expanded programme on immunisation (EPI) vaccines.

111 Immunisation experiments performed in rabbits demonstrat

112 scaled up selective primary health care (eg, immunisation, family planning), and 14 have progressed t

113 : maternal and newborn health, child health, immunisation, family planning, HIV/AIDS, and malaria.

114 t control policy that relies only on routine immunisation for 20 years with discounted costs of more

115 Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, H

116 =320 and 284), given at the second and third immunisations for diphtheria, pertussis, and tetanus, an

117 outinely given vaccines require two or three immunisations for full protective efficacy.

118 tegy of the Global Alliance for Vaccines and Immunisation (GAVI) Alliance is helping to implement vac

119 es that the Global Alliance for Vaccines and Immunisation (GAVI) face now that these new vaccines are

120 (SIAs) and Global Alliance for Vaccines and Immunisation (GAVI) funding in replacing disposable and

121 The Global Alliance for Vaccines and Immunisation (GAVI) was created in 1999 to enable even t

122 aign and the Global Alliance on Vaccines and Immunisations (GAVI).

123 uenza infections in infants aged 0-6 months, immunisation had an overall efficacy for the combined co

124 Maternal immunisation has the potential to substantially reduce m

125 ternal and child health services and routine immunisation (health camps), including OPV (arm B), or a

126 vestigated whether paternal mononuclear cell immunisation improves the rate of successful pregnancies

127 of factors affecting the uptake of childhood immunisation in developed countries.

128 and infants of year-round maternal influenza immunisation in Nepal, where influenza viruses circulate

129 uce infection by HIV-1, and the role of such immunisation in preventive and therapeutic vaccination s

130 levels of measles, mumps, and rubella (MMR) immunisation in the UK and the continuing debate on how

131 y and memory are well understood to underpin immunisation in vertebrates, it has been somewhat surpri

132 e at age 1 year to BCG, tetanus, and measles immunisation; incidence of infectious diseases during in

133 Coverage of child immunisation increased the most (21% of children in 2000

134 hat gathered experts across several maternal immunisation initiatives-group B streptococcus, respirat

135 importance of maintaining and increasing the immunisation intensity to complete eradication and to il

136 Immunisation is possible with monovalent varicella vacci

137 pulsory vaccinations are being introduced or immunisation laws refined.

138 s are undergoing clinical trials, so passive immunisation might finally become an accessible, afforda

139 After booster immunisations, most of the immune responses showed the i

140 Our results suggest that the intensity of immunisation must be increased to achieve eradication, a

141 HPV immunisation of adolescent girls is expected to have a s

142 Immunisation of animals with BHPIV3/SARS-S induced the p

143 utic cancer vaccine, and the successful mass immunisation of children with meningococcal conjugate va

144 These data support the concept that immunisation of devils with DFTD cancer cells can succes

145 Immunisation of mice with different Opa variants elicite

146 Immunisation of mice with HAd-H5HA provided effective pr

147 pa bactericidal antibody responses following immunisation of mice with recombinant Opa were specific

148 onses in social ants that lead to the active immunisation of nestmates by infected individuals.

149 We investigated whether immunisation of patients who had symptomless HIV-1 infec

150 Immunisation of patients with Alzheimer's disease with f

151 Postinfection immunisation of symptom-free HIV-infected patients with

152 oped an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of

153 removes the need for selection using animal immunisation or in vitro techniques such as phage or rib

154 ocused health programmes in family planning, immunisation, oral rehydration therapy, maternal and chi

155 otential causal factors including infection, immunisations, physical and emotional stressors, climate

156 Viral vectors are a potent immunisation platform, benefiting from intrinsic immuno-

157 edge regarding the immunobiology of maternal immunisation prevent the optimal design and application

158 was introduced into the Australian National Immunisation Program in 2007.

159 role of school nurses in delivering the HPV immunisation programme and their impact on minimising he

160 g introduction of rubella vaccine into their immunisation programme assess their burden of congenital

161 interviewed, primarily school nurses and HPV immunisation programme coordinators.

162 In the routine immunisation programme in Brazil, PCV10 prevents invasiv

163 ningococcal disease-into the national infant immunisation programme in September, 2015.

164 rain were selected and used for the national immunisation programme in the United Kingdom: an adjuvan

165 UK The HPV immunisation programme is primarily delivered by school

166 or children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vac

167 A strategy modelled after China's immunisation programme, whereby care is provided close t

168 6 and 14 weeks into South Africa's national immunisation programme.

169 in many developed countries by an effective immunisation programme.

170 rotavirus vaccine into its routine national immunisation programme.

171 nB, Bexsero) into a publicly funded national immunisation programme.

172 ourably with that of, for example, childhood immunisation programmes ($12-17 per DALY).

173 ght modulate coverage could inform effective immunisation programmes and policies.

174 g understanding of the delivery processes of immunisation programmes and this impact on health inequa

175 troduced rotavirus vaccination into national immunisation programmes and, subsequently, the burden of

176 troduction of rotavirus vaccines into global immunisation programmes has been a high priority for man

177 red in the past decade as a direct result of immunisation programmes in Europe, Canada, and Australia

178 accination has contributed to the success of immunisation programmes in the USA and Australia, yet th

179 nfluenza-associated disease burden, existing immunisation programmes might be less cost-effective.

180 pproximate measures of the susceptibility of immunisation programmes to coverage losses, with an aim

181 ctivated poliovirus vaccine (IPV) in routine immunisation programmes to eliminate vaccine-associated

182 e concerns over time and location could help immunisation programmes to tailor more effective and tim

183 uced a rotavirus vaccine into their national immunisation programmes, we excluded data subsequent to

184 ttractive target for preventive and reactive immunisation programmes.

185 ategies as crucial components in future mass immunisation programmes.

186 H1N1 strain, many countries have begun mass immunisation programmes.

187 al care and the widespread implementation of immunisation programmes.

188 ent, and the financial support to strengthen immunisation programmes.

189 ssessments of the strength and resilience of immunisation programmes.

190 for the inclusion of Dengvaxia into existing immunisation programmes.

191 he UK following successful implementation of immunisation programmes.

192 erage was maintained than in countries where immunisation programs were compromised by anti-vaccine m

193 ucture and diagnostic facilities also hamper immunisation projects in developing countries.

194 d funding to family planning, nutrition, and immunisation projects were noted in 2011 and 2012.

195 delivery of preventive interventions such as immunisation, promotion of healthy behaviour, and mobili

196 PCV13 immunisation provides a robust strategy for combating pn

197 igh number of doctors per head, high measles immunisation rates, few health-sector donors, and high d

198 eness of pneumococcal conjugate vaccine, and immunisation rates.

199 A move to mucosal immunisation rather than use of the syringe and needle w

200 We analysed the immunisation records of 58 cases and 306 controls.

201 Immunisation reduced maternal febrile influenza-like ill

202 Maternal immunisation reduced the rates of low birthweight by 15%

203 ata, sexual health clinic data, and National Immunisation Register data were linked via patients' uni

204 es were verified by the Australian Childhood Immunisation Register, which was also used to identify a

205 e was assessed from the Australian Childhood Immunisation Register.

206 were obtained from the Australian Childhood Immunisation Register.

207 biodistribution profile was reflected in the immunisation response, where lower levels of IgG2b antib

208 gate vaccine (PCV13) into the routine infant immunisation schedule in November 2011.

209 vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012.

210 he USA, IPV has been included in the routine immunisation schedule since 1997.

211 fter completion of the expanded programme of immunisation schedule): 1/3 IPV-Al 98.5% (n=202, type 1)

212 In 2010, PCV13 replaced PCV7 in the US immunisation schedule.

213 ction of vaccines might need modification of immunisation schedules and delivery procedures.

214 ntries opting for one dose of IPV in routine immunisation schedules during this transition because of

215 adication strategy to introduce IPV into the immunisation schedules of all countries.

216 cohorts remains low, but alternative routine immunisation schedules should be considered to ensure hi

217 assess the immunogenicity of bOPV in routine immunisation schedules.

218 44 phase 3 trial might benefit from extended immunisation schedules.

219 idis can be incorporated into routine infant-immunisation schedules.

220 Childhood immunisation series could thus be started more opportune

221 age these technologies to support demand for immunisation services and improve vaccine coverage.

222 antenatal care, institutional delivery, and immunisation services in six of seven health districts i

223 VI recipient countries from 1995 to 2004 and immunisation services support (ISS) and non-ISS expendit

224 -oriented initiatives such as UCI and GAVI's immunisation services support (ISS) might encourage over

225 NTERPRETATION: Year-round maternal influenza immunisation significantly reduced maternal influenza-li

226 for attachment informative behaviours in the immunisation situation should be developed and tested in

227 Following triple homologous immunisation, small unilamellar vesicles (SUVs) with no

228 on-going, outbreak since the advent of mass immunisation started within Russia and the newly indepen

229 of adverse events was similar regardless of immunisation status.

230 ild marriage, female genital mutilation, and immunisation), stigma and harm reduction, violence again

231 assess the potential effect of different RSV immunisation strategies (targeting vaccination for infan

232 Our results show that perinatal immunisation strategies for children aged younger than 6

233 led to consideration of additional maternal immunisation strategies to prevent group B streptococcus

234 education, and the strengthening of routine immunisation systems.

235 ventions against the two diseases to 80% and immunisation to 90% would eliminate more than two-thirds

236 ade in understanding the immune response and immunisation to HIV, and new ideas for candidate vaccine

237 requires two (IPV2) or three (IPV1 and IPV3) immunisations to induce similar responses.

238 als receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody ti

239 initiatives such as the Universal Childhood Immunisation (UCI) campaign and the Global Alliance on V

240 eminders and monetary incentives can improve immunisation uptake in Kenya.

241 OPV, IPV, and routine extended programme on immunisation vaccines and changes in the proportion of u

242 available for analysis 1 month after booster immunisation versus 86 in group 2.

243 are the relative immunogenicity of Nanopatch immunisation versus intramuscular injection in rats, usi

244 Infant immunisation videos were observed and coded for parentin

245 ers before scheduled pentavalent and measles immunisation visits.

246 ies of factors affecting uptake of childhood immunisation was combined and assessed.

247 y, Poland, and the USA) with countries where immunisation was disrupted by anti-vaccine movements (Sw

248 At 56 days post-immunisation, we found that rats with vasculitis had a s

249 Four primary immunisations, weekly for 4 weeks, containing Vacc-4x (o

250 Immune responses after subsequent immunisation were evaluated using haemagglutination-inhi

251 Measles and tetanus toxoid immunisation were not affected.

252 Booster immunisations were given at weeks 16 and 18.

253 st rapid increases in coverage were seen for immunisation, which also received significant investment

254 after just one (IPV2) or two (IPV1 and IPV3) immunisations, while IM injection requires two (IPV2) or

255 ease antibody responses to gp140 after I.Vag immunisations, while in contrast PEI and Chitosan were a

256 e and non-human primates after intramuscular immunisation with a candidate recombinant measles vaccin

257 ndomisation system to receive transcutaneous immunisation with a patch containing 37.5 mug of ETEC LT

258 se I randomised, placebo-controlled trial of immunisation with Abeta(42) (AN1792, Elan Pharmaceutical

259 Although immunisation with Abeta(42) resulted in clearance of amy

260 Passive immunisation with anti-prion protein antibodies prevents

261 ting tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of compet

262 ) to different single doses of intramuscular immunisation with ChAd3-EBO-Z: Malians received 1 x 10(1

263 elect the most promising candidates, such as immunisation with DNA.

264 Immunisation with either high-dose or low-dose DENVax fo

265 Immunisation with fully synthetic three-component vaccin

266 Immunisation with hepatitis B virus vaccine is the most

267 portionate reporting of adverse events after immunisation with IPV-containing vaccines compared with

268 e-poor countries has focused on early infant immunisation with little emphasis on protection in late

269 A cohort study raised the possibility that immunisation with live attenuated measles vaccine, which

270 proaches, including the recent innovation of immunisation with nucleic acids.

271 91 were assigned immunisation with paternal mononuclear cells (treatment)

272 Immunisation with paternal mononuclear cells does not im

273 Immunisation with paternal mononuclear cells is used as

274 B-cell tolerance to human PTH was broken by immunisation with PTH peptides in adjuvant.

275 Routine infant immunisation with seven-valent pneumococcal conjugate va

276 aternal mononuclear cells (treatment) and 92 immunisation with sterile saline (control).

277 We tested whether an immunisation with synthetic human and bovine PTH peptide

278 l tetanus has not been eliminated to provide immunisation with tetanus toxoid to women of childbearin

279 Although easily prevented by maternal immunisation with tetanus toxoid vaccine, and aseptic ob

280 Immunisation with the adjuvanted split vaccine induced s

281 en under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C c

282 t key serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), but i

283 enge was achieved after low dose (20PFU) pre-immunisation with this mutant.

284 ty, immunogenicity, and efficacy of maternal immunisation with trivalent inactivated influenza vaccin

285 in vaginal secretions were achieved after IN immunisations with PEI and Chitosan.

286 ing antibodies in all dose cohorts after one immunisation, with seroconversion rates of 44% (n=4) in

287 d money if their child was timely immunised (immunisation within 2 weeks of the due date).

288 A strategy of routine childhood and adult immunisation would have prevented 61% of cases had this